DYNE-101 在 1 型强直性营养不良参与者中的安全性、耐受性、药效学、疗效和药代动力学研究 (ACHIEVE)
一项随机、安慰剂对照、多剂量递增研究,评估 DYNE-101 对 1 型强直性肌营养不良症参与者的安全性、耐受性、药效学、疗效和药代动力学
The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).
The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (208 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Berlin、德国、10117
- Charité - Universitätsmedizin Berlin
-
Munich、德国、80336
- Ludwig Maximilians University, Munich - Friedrich Baur Institut
-
-
-
-
-
Milan、意大利、20162
- Centro Clinico Nemo
-
Rome、意大利、00168
- Fondazione Policlinico Universitario A Gemelli-Rome
-
-
-
-
-
Auckland、新西兰、1023
- NZCR Auckland
-
-
-
-
-
Nantes、法国、44093
- CHU de Nantes
-
Paris、法国、75013
- Institut de Myologie
-
-
-
-
Victoria
-
Fitzroy、Victoria、澳大利亚、3065
- St. Vincent's Hospital
-
-
-
-
California
-
Stanford、California、美国、94305
- Stanford University
-
-
Florida
-
Gainesville、Florida、美国、32610
- University of Florida College of Medicine
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University School of Medicine
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Washington University in St. Louis
-
-
New York
-
Rochester、New York、美国、14642
- University of Rochester Medical Center
-
-
Texas
-
Denton、Texas、美国、76208
- Neurology Rare Disease Center
-
-
Virginia
-
Richmond、Virginia、美国、23298
- Virginia Commonwealth University (VCU)
-
-
-
-
-
London、英国、NW1 2BU
- University College London Hospitals
-
Newcastle upon Tyne、英国
- John Walton Muscular Dystrophy Research Centre
-
Salford、英国、M6 8HD
- Salford Royal Hospital
-
-
-
-
-
Nijmegen、荷兰
- Radboud Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of DM1 with trinucleotide repeat size >100.
- Age of onset of DM1 muscle symptoms ≥12 years.
- Clinically apparent myotonia equivalent to hand opening time of at least 2 seconds in the opinion of the Investigator.
- Hand grip strength and ankle dorsiflexion strength.
- Able to complete 10-MWRT, stair ascend/descend (MAD cohorts only), and 5×STS at screening without the use of assistive devices such as canes, walkers, or orthoses.
Exclusion Criteria:
- History of major surgical procedure within 12 weeks prior to the start of investigative product administration or an expectation of a major surgical procedure (eg, implantation of cardiac defibrillator) during the study.
- History of anaphylaxis.
- Medical condition other than DM1 that would significantly impact ambulation or participation in functional assessments.
- Treatment with medications that can improve myotonia within a period of 5 half-lives of the medication prior to performing screening assessments.
- Electrocardiogram (ECG) with the corrected QT interval by Fridericia's Formula (QTcF) ≥450 milliseconds (ms) in men and QTcF ≥460 ms in women, PR ≥240 ms, left bundle-branch block, or a conduction defect, which is clinically significant in the opinion of the Investigator.
- Percent predicted forced vital capacity (FVC) <50%.
- History of tibialis anterior biopsy within 3 months of Day 1 or planning to undergo tibialis anterior biopsies during study period for reasons unrelated to the study.
- Participant has a history of suicide attempt, suicidal behavior, or has any suicidal ideation within 6 months prior to Screening that meets criteria at a level of 4 or 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) or who, in the opinion of the Investigator, is at significant risk to commit suicide.
- Use of glucagon-like peptide 1 (GLP-1) agonist medications including semaglutide, dulaglutide, liraglutide, exenatide, or tirzepatide within a period of 5 half-lives of the medication prior to performing screening assessments.
- Significant weight loss during study participation may impact weight-based dosing, performance on muscle function assessments, and pharmacodynamic (PD) biomarkers.
Note: Other inclusion and exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MAD Cohort: Placebo-Controlled Period: DYNE-101
Participants will be randomized to receive ascending doses of DYNE-101, once every 4 weeks (Q4W) or once every 8 weeks (Q8W) for up to 24 weeks. |
Administered by IV infusion |
|
安慰剂比较:MAD Cohort: Placebo-Controlled Period: Placebo
Participants will be randomized to receive DYNE-101 matching placebo, Q4W or Q8W for up to 24 weeks. |
Administered by IV infusion |
|
实验性的:MAD Cohort: Treatment Period: DYNE-101
Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q4W or Q8W for up to 24 weeks. Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q4W or Q8W for up to 24 weeks. |
Administered by IV infusion Administered by IV infusion |
|
实验性的:MAD Cohort: Long-Term Extension Period: DYNE-101
Participants will receive DYNE-101, Q4W or Q8W for up to 208 weeks. |
Administered by IV infusion |
|
实验性的:Dose Expansion Cohort: Placebo-Controlled Period: DYNE-101
Participants will receive DYNE-101, Q8W for up to 24 weeks. |
Administered by IV infusion |
|
实验性的:Dose Expansion Cohort: Placebo-Controlled Period: Placebo
Participants will receive DYNE-101 matching placebo, Q8W for up to 24 weeks. |
Administered by IV infusion |
|
实验性的:Dose Expansion Cohort: Treatment Period: DYNE-101
Participants who receive DYNE-101 in Placebo-Controlled Period will continue to receive DYNE-101, Q8W for up to 24 weeks. Participants who receive placebo in Placebo-Controlled Period will receive DYNE-101, Q8W for up to 24 weeks. |
Administered by IV infusion Administered by IV infusion |
|
实验性的:Dose Expansion Cohort: Long-Term Extension Period: DYNE-101
Participants will receive DYNE-101, Q8W for up to 208 weeks. |
Administered by IV infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
剂量扩展队列:通过视频打开时间(VHOT)来衡量的Myotonia的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
MAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
大体时间:Through study completion, up to Week 257
|
Through study completion, up to Week 257
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
MAD队列:从肌肉组织中肌酸肌酸蛋白激酶(DMPK)核糖核酸(RNA)表达的基线变化
大体时间:基线到第45周
|
基线到第45周
|
|
疯狂的队列:从基线在手抓握放松时间中变化
大体时间:基线到第121周
|
基线到第121周
|
|
疯狂的队列:从楼梯式ASCEND/DESCEND测试中的基线更改
大体时间:基线到第121周
|
基线到第121周
|
|
MAD队列:反义寡核苷酸(ASO)肌肉组织中的Dyne-101浓度
大体时间:直到第45周
|
直到第45周
|
|
疯狂队列:从骨骼肌组织中的复合替代剪接指数(CASI)中的基线变化
大体时间:基线到第45周
|
基线到第45周
|
|
剂量膨胀队列:从CASI中的基线变化骨骼肌肉组织
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从QMT总数的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从10-mwrt中的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从基线变化5×STS
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从9-HPT中的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从肌发育性营养不良健康指数(MDHI)总分的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩张队列:患者全球变化印象(PGI-C)
大体时间:基线到第25周
|
基线到第25周
|
|
临床医生全球变化印象(CGI-C)
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从患者全球严重程度(PGI-S)的基线变化(PGI-S)
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩张队列:从临床医生全球严重程度印象(CGI-S)的基线变化(CGI-S)
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从MDHI子量表分数中的基线变化
大体时间:基线到第25周
|
基线到第25周
|
|
剂量膨胀队列:从基线在Myotonic营养不良1型活动和参与量表(DM1-ACTIV^C)总分
大体时间:基线到第25周
|
基线到第25周
|
|
剂量扩展队列:从基线(以百分比为预测的手柄强度)变化
大体时间:基线到第25周
|
基线到第25周
|
|
MAD Cohorts: Change From Baseline in Myotonia as Measured by vHOT
大体时间:Baseline up to Week 257
|
Baseline up to Week 257
|
|
MAD Cohorts: Change From Baseline in Quantitative Myometry Testing (QMT)
大体时间:Baseline up to Week 257
|
Baseline up to Week 257
|
|
MAD Cohorts: Change From Baseline in 10-Meter Walk/Run Test (10-MWRT)
大体时间:Baseline up to Week 257
|
Baseline up to Week 257
|
|
MAD Cohorts: Change From Baseline in 5 Times Sit to Stand (5×STS)
大体时间:Baseline up to Week 257
|
Baseline up to Week 257
|
|
MAD Cohorts: Change From Baseline in 9-Hole Peg Test (9-HPT)
大体时间:Baseline up to Week 257
|
Baseline up to Week 257
|
|
MAD Cohorts: Maximum Observed Plasma Drug Concentration (Cmax) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Time to Maximum Observed Plasma Concentration (tmax) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration (AUCtlast) of DYNE-101
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Area Under the Concentration-time Curve Extrapolated to Infinity (AUC∞) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Apparent Terminal Elimination Rate Constant (λz) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Apparent Terminal Elimination Half-Life (t1/2) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Clearance (CL) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Volume of Distribution at the Terminal Phase (Vz) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Volume of Distribution at Steady State (Vss) of DYNE-101 in Plasma
大体时间:Pre-dose, and at multiple timepoints up to Week 257
|
Pre-dose, and at multiple timepoints up to Week 257
|
|
MAD Cohorts: Number of Participants With Antidrug Antibodies (ADAs)
大体时间:Up to Week 257
|
Up to Week 257
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.